Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group.
about
Immunoglobulin for preventing respiratory syncytial virus infectionBiochemical prevention and treatment of viral infections - a new paradigm in medicine for infectious diseasesThe use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infectionRespiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.Pharmacokinetics of intravenous immunoglobulin: a systematic review.Bronchiolitis.Active and passive immunisation against respiratory syncytial virus.Immunoglobulin for preventing respiratory syncytial virus infection.Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathologySafety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin.Respiratory syncytial virus infections.Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention.Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.Antibody-based therapies as anti-infective agents.Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.Mechanisms of immunoglobulin action: observations on Kawasaki syndrome and RSV prophylaxis.Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action.Respiratory syncytial virus immune globulin intravenous.Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028).Pharmacokinetics of a benzodithiin (RD3-0028) following aerosol treatment in rat.Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin.The therapeutic potential of monoclonal antibodies against respiratory syncytial virus.Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina
P2860
Q24245599-5B45AC5A-774E-4C2D-9964-CFF34076A8FAQ24801934-E6F9E934-80CF-42AC-AD17-0842A3BB38D1Q26864494-4CB56340-5FBD-4F7A-89BC-85D2B51A6500Q30240274-297FE442-CCBC-4056-ABED-27FAFB9051E6Q33371277-59560AE0-C274-4C5B-94AE-C9584D2988D2Q33446856-2B31DB61-D2D3-4602-B491-42B14E98C6A4Q33782438-65D2D65A-B78E-4B7F-B7C2-A1EA0B2B3A5AQ33909278-E4772392-A913-4B71-A5A4-4CB5440A1C1BQ34307704-F003C67A-38AF-4E5A-83FE-D9A93F4DF074Q34364942-11AA871C-A519-48A8-AD72-047DB5F653DCQ35112303-28A2DBBF-8874-4610-9196-7F9C851D6297Q35480437-4C71F0F5-3BDB-450B-8141-51CEC8707562Q36922280-2CF27C2E-E63C-4754-9FD3-C46C681BDAEBQ37841264-C7F02882-411B-421C-A38A-B17CAAD83E7FQ37841269-628A30F2-D671-4966-91ED-4669DAC1133CQ38671952-389D00F2-FE33-4F3C-A6F9-4276E19E86F3Q39216839-C97D6D36-CE52-40F1-98D5-806FC2A0A106Q39866426-3AA3A0F5-7336-4AF4-990A-1CDC43E2A1BEQ40633344-5A4FF064-4A01-4224-9AAD-7E42B905236AQ40703838-3AED168B-03AE-4D04-BC4C-403EA8948EB9Q41316287-4A038515-7C9F-411F-841B-E8E9BA0C91F7Q43724047-9F47C7A7-B1B7-4003-AF80-C0E4213B5386Q43872054-106FB345-C0D4-4E07-94D9-F9993B55CC6DQ44923546-E13BDF24-080D-4CB5-BFD7-D7D849BB4BF6Q45439981-7E2714B7-DF61-49E0-9B11-D3AEBE291602Q51718949-5FAB25E4-5126-4C45-88F3-9C1641F895FBQ58806120-37EF83FF-BAEF-4888-B836-B3DA5E21ABA4
P2860
Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Use of intravenous gamma globu ...... netics. The RSVIG Study Group.
@en
type
label
Use of intravenous gamma globu ...... netics. The RSVIG Study Group.
@en
prefLabel
Use of intravenous gamma globu ...... netics. The RSVIG Study Group.
@en
P2093
P2860
P356
P1476
Use of intravenous gamma globu ...... netics. The RSVIG Study Group.
@en
P2093
J R Groothuis
V G Hemming
W Rodriguez
P2860
P304
P356
10.1128/AAC.35.7.1469
P407
P577
1991-07-01T00:00:00Z